| Nov 19 |
Allogene Therapeutics Announces Participation in December Investor Conferences
|
| Nov 18 |
Allogene Therapeutics Presents Preclinical Data for ALLO-329, an Allogeneic CD19/CD70 Dual CAR T for the Treatment of Autoimmune Disease at the American College of Rheumatology (ACR) Convergence
|
| Nov 14 |
Syros Stock Plunges as Lead Cancer Study Fails to Meet Primary Goal
|
| Nov 8 |
Allogene's Q3 Loss Narrower Than Expected, Sales Nil
|
| Nov 8 |
Allogene Therapeutics Inc (ALLO) Q3 2024 Earnings Call Highlights: Financial Resilience Amidst ...
|
| Nov 8 |
Allogene Therapeutics, Inc. (ALLO) Q3 2024 Earnings Call Transcript
|
| Nov 7 |
Allogene Therapeutics GAAP EPS of -$0.32 beats by $0.01
|
| Nov 7 |
Allogene Therapeutics: Q3 Earnings Snapshot
|
| Nov 7 |
Allogene Therapeutics Reports Third Quarter 2024 Financial Results and Business Update
|
| Nov 7 |
CPRX Q3 Earnings & Revenues Beat Estimates, '24 View Raised, Stock Up
|
